IO Biotech to participate in panel discussion at Biotech Showcase in San Francisco on January 7th
Copenhagen, Denmark – January 5, 2019: IO Biotech’s CEO, Mai-Britt Zocca, is to participate in the panel discussion “Investing in Next Gen Immunotherapies: Moving the Checkpoint Inhibitors to the Next Level” at Biotech Showcase in San Francisco on January 7, 2019 during the JPM week.
Description of panel discussion: "While the frenzy around funding Immuno-Oncology agents has started to settle down from its peak in 2015-2016, the question remains open as to which if any of these many “first generation” programs for solid tumors looking to enhance the activity of checkpoint inhibitors and/or attempting to render colder tumors hotter will actually provide the next big shift in clinical management. Data to date has been disappointing to mixed at best. When looking to the future of immunotherapy, one wonders if there will only be for the foreseeable future more incremental advances. But where are the next big paradigm shifts going to be, where is the next great target that will supersize foundational checkpoint therapy? This panel will probe these issues especially as they relate to creating value not only for investors and potential partners but most critically for patients."
IO Biotech will participate in the discussion together with Bloomberg Intelligence, New Enterprise Associates (NEA), Surface Oncology and Compass Therapeutics, and the discussion will be moderated by Defined Health.
The discussion is to take place at Monday, January 7, 2019, 8:00 – 9:00 AM in Hilton Union Square.